BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA : RETROSPECTIVE ANALYSIS OF AVAglio

Olivier Chinot,Josep Garcia,Sylvie Romain,Cedric Revil,Timothy F. Cloughesy,Warren P. Mason,Ryo Nishikawa,Roger Henriksson,Frank Saran,Antoine F. Carpentier,Khê Hoang-Xuan,Petr Kavan,Dana Cernea,Alba A. Brandes,Yannick Kerloeguen,Christoph Mancao,L’Houcine Ouafik,L. E. Abrey,Wolfgang Wick,Emeline Tabouret

BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA : RETROSPECTIVE ANALYSIS OF AVAglio

2016

BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA : RETROSPECTIVE ANALYSIS OF AVAglio

Keywords:

Glioblastoma
Bevacizumab
Immunology
Matrix metalloproteinase
Pathology
MMP9
Medicine
newly diagnosed
retrospective analysis
overall survival
matrix metalloproteinase 9

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations